Should I buy or sell Alterity Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alterity Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHE shares. View ATHE analyst ratings or view top-rated stocks .

What is Alterity Therapeutics' stock price target for 2024?

1 equities research analysts have issued twelve-month price objectives for Alterity Therapeutics' stock. Their ATHE share price targets range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 238.2% from the stock's current price. View analysts price targets for ATHE or view top-rated stocks among Wall Street analysts .

How have ATHE shares performed in 2024?

Alterity Therapeutics' stock was trading at $2.49 on January 1st, 2024. Since then, ATHE stock has decreased by 16.9% and is now trading at $2.07. View the best growth stocks for 2024 here .

Are investors shorting Alterity Therapeutics?

Alterity Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 23,100 shares, a drop of 12.5% from the March 15th total of 26,400 shares. Based on an average daily trading volume, of 39,600 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.3% of the shares of the stock are short sold. View Alterity Therapeutics' Short Interest .

When did Alterity Therapeutics' stock split?

Shares of Alterity Therapeutics reverse split on the morning of Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Alterity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alterity Therapeutics investors own include Achillion Pharmaceuticals (ACHN) , ACADIA Pharmaceuticals (ACAD) , Arbutus Biopharma (ABUS) , Abacus Property Group (ABP) , Advanced BioMedical Technologies (ABMT) , Abiomed (ABMD) , ARCA biopharma (ABIO) , Abeona Therapeutics (ABEO) and Abcam (ABCZY) .

How do I buy shares of Alterity Therapeutics?

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATHE

Alterity Therapeutics (ATHE) Stock Price, News & Analysis

→ A new way to collect income from stocks (From DTI) (Ad)

Free ATHE Stock Alerts

$2.07

+0.02 (+0.98%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.91
▼
$2.20
50-Day Range: $1.66
▼
$2.94
52-Week Range: $1.55
▼
$5.41

Volume: 124,793 shs
Average Volume: 79,034 shs
Market Capitalization: $9.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Alterity Therapeutics alerts:

Alterity Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 238.2% Upside
$7.00 Price Target
Short Interest: Healthy
0.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.25) to ($0.13) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.36 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Alterity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Alterity Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.28% of the float of Alterity Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Alterity Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Alterity Therapeutics has recently decreased by 12.50%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Alterity Therapeutics does not currently pay a dividend.
Dividend Growth
Alterity Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATHE.

3.0

News and Social Media Coverage

News Sentiment
Alterity Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Alterity Therapeutics this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for ATHE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
1 people have added Alterity Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.14% of the stock of Alterity Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Alterity Therapeutics are expected to grow in the coming year, from ($0.25) to ($0.13) per share.
Price to Book Value per Share Ratio
Alterity Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Alterity Therapeutics Stock (NASDAQ:ATHE)

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

ATHE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATHE Stock News Headlines

April 17, 2024 | finance.yahoo.com

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

April 10, 2024 | globenewswire.com

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

April 17, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

April 10, 2024 | americanbankingnews.com

Critical Analysis: Alterity Therapeutics (NASDAQ:ATHE) vs. Antibe Therapeutics (OTCMKTS:ATBPF)

April 5, 2024 | finance.yahoo.com

Alterity Therapeutics Limited (ATHE)

March 26, 2024 | globenewswire.com

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

March 24, 2024 | morningstar.com

Alterity Therapeutics Ltd ADR ATHE

March 22, 2024 | seekingalpha.com

ATHE Alterity Therapeutics Limited

April 17, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

March 22, 2024 | wsj.com

Alterity Therapeutics Ltd. ADR

February 23, 2024 | msn.com

Alterity Therapeutics drops on capital raise

February 22, 2024 | benzinga.com

Alterity Therapeutics Stock (NASDAQ:ATHE), Short Interest Report

February 20, 2024 | finance.yahoo.com

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

February 20, 2024 | globenewswire.com

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

January 29, 2024 | finance.yahoo.com

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

January 22, 2024 | finance.yahoo.com

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

December 21, 2023 | finanznachrichten.de

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

December 4, 2023 | finance.yahoo.com

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

December 4, 2023 | marketwatch.com

Alterity Therapeutics Shares Up Fivefold on New Parkinson's Drug Data

December 4, 2023 | msn.com

Why Is Neurodegenerative Disease-Focused Alterity Therapeutics Stock Trading Over 200% Higher Today?

December 4, 2023 | finance.yahoo.com

Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data

December 4, 2023 | finance.yahoo.com

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

November 27, 2023 | finance.yahoo.com

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

November 22, 2023 | finance.yahoo.com

Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation Is Looking A Bit Stretched At The Moment

November 22, 2023 | msn.com

Alterity Therapeutics, Edesa Biotech among healthcare movers

November 22, 2023 | marketwatch.com

Alterity Therapeutics ADRs Shares Dive 31% on Raised Capital

November 16, 2023 | finanznachrichten.de

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

See More Headlines

Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/17/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ATHE
CUSIP: N/A
CIK: 1131343
Web: www.alteritytherapeutics.com
Phone: (139) 349-4906
Fax: 61-3-9348-0377
Employees: 11
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $10.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +264.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.89
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $3.37 million
Price / Sales: 2.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.78 per share
Price / Book: 0.51

Miscellaneous

Outstanding Shares: 4,670,000
Free Float: 2,859,000
Market Cap: $8.97 million
Optionable: Not Optionable
Beta: 0.94

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Geoffrey Paul Kempler B.Sc. (Age 69)
Co-Founder & Non-Executive Chairman
Comp: $204.84k
Dr. David A. Stamler M.D. (Age 63)
Chief Executive Officer
Comp: $605.41k
Mr. Phillip Allen Hains BBus(Acc) (Age 65)
C.A., M.B.A., CFO & Company Secretary
Dr. Rudolph Emile Tanzi Ph.D. (Age 65)
Chief Scientific Advisor and Member of Research & Development Advisory Board
Dr. Steven D. Targum
Chief Medical Advisor
Dr. Robert Cherny
Head of Research

Key Competitors

View All Competitors

Institutional Ownership

Virtu Financial LLC
Bought 10,799 shares on 2/26/2024
Ownership: 0.265%

View All Institutional Transactions

ATHE Stock Analysis - Frequently Asked Questions

Should I buy or sell Alterity Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alterity Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHE shares.
View ATHE analyst ratings or view top-rated stocks.
What is Alterity Therapeutics' stock price target for 2024?: 1 equities research analysts have issued twelve-month price objectives for Alterity Therapeutics' stock. Their ATHE share price targets range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 238.2% from the stock's current price.
View analysts price targets for ATHE or view top-rated stocks among Wall Street analysts.
How have ATHE shares performed in 2024?: Alterity Therapeutics' stock was trading at $2.49 on January 1st, 2024. Since then, ATHE stock has decreased by 16.9% and is now trading at $2.07.
View the best growth stocks for 2024 here.
Are investors shorting Alterity Therapeutics?: Alterity Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 23,100 shares, a drop of 12.5% from the March 15th total of 26,400 shares. Based on an average daily trading volume, of 39,600 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.3% of the shares of the stock are short sold.
View Alterity Therapeutics' Short Interest.

When did Alterity Therapeutics' stock split?: Shares of Alterity Therapeutics reverse split on the morning of Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Alterity Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alterity Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).
How do I buy shares of Alterity Therapeutics?: Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATHE) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Alterity Therapeutics (ATHE) Stock Price, News & Analysis

Alterity Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Alterity Therapeutics Stock (NASDAQ:ATHE)

ATHE Stock Price History

ATHE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ATHE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™